Stay updated on Psilocybin Adjunct for Treatment-Resistant Depression Clinical Trial
Sign up to get notified when there's something new on the Psilocybin Adjunct for Treatment-Resistant Depression Clinical Trial page.

Latest updates to the Psilocybin Adjunct for Treatment-Resistant Depression Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe record describes a completed Phase 2 study of psilocybin as an adjunctive therapy for treatment-resistant depression, including participant eligibility, study design, and outcome measures. It also provides study locations, investigator details, and downloadable protocol and analysis documents.SummaryDifference45%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site as revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces that NIH websites are transitioning from the term “Artificial Intelligence” to “Super Intelligence.” It appears above the page’s 403 error message.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 while the page continued to show a 403 error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the usual study details with an access-denied screen.SummaryDifference18%

Stay in the know with updates to Psilocybin Adjunct for Treatment-Resistant Depression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psilocybin Adjunct for Treatment-Resistant Depression Clinical Trial page.